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Thresholds in Cost-Effectiveness Analysis—More of the Story
 
To The Editor—Thanks are due to Eichler et al. [1]
for their excellent overview of the history and issues
concerning the various thresholds used as a bench-
mark in many cost-effectiveness studies. The inter-
national picture they present is especially welcome.
I offer the following to complement what Eichler
and colleagues reported:
1. In reviewing the various thresholds used in the
literature, Eichler et al. (citing Hirth et al. [2])
note the dialysis standard of $50,000 per qual-
ity-adjusted life year (QALY) as the “purported
cost/QALY to the Medicare program for
patients with chronic renal failure . . . [and
which] might have been based on considerable
underestimation of the program’s true costs
[1].” From accounts published by Richard Ret-
tig of RAND, we ﬁnd that, except in the broad-
est sense, costs were not clearly enumerated. At
the time the expansion of Medicare to patients
with chronic renal failure was before Congress
in 1972, the Social Security Administration’s
Ofﬁce of the Actuary provided estimates of ﬁrst
year costs of the expansion to be between $100
million and $500 million. Senator Vance
Hartke, in proposing the kidney entitlement
amendment during Senate hearings, offered
estimates of $75 million for the ﬁrst year and
$250 million for the fourth year. Hartke also
stated that per patient costs of dialysis ranged
from $19,000 per year for the ﬁrst year of home
dialysis to up to $25,000 per year for treatment
in a hospital, ﬁgures that were provided to
Hartke by the National Kidney Foundation and
physicians who were also advocating for the
entitlement. These reported events, then, sug-
gest that the use of any dollar amount as imply-
ing willingness to pay for a medical or health
intervention by the federal government—and
by extension, the $50,000 threshold—appears
to be without basis. Of particular note is how
testimony in support of the amendment
included dialyzing a patient—who volunteered
to do this—before members of the House Ways
and Means Committee. Unbeknownst to this
legislative audience was that the dialysis session
was quickly aborted as the patient went into
ventricular tachycardia during the procedure.
The legislative audience, however, believed they
had witnessed a completed procedure [3,4].
Two items related to Laupacis et al.’s [5] rec-
ommended guidelines for technology adoption
deserve mention. First, Eichler et al. correctly
present these guidelines as they were offered in
1992. Nevertheless, this work is often and inap-
propriately cited as the source of the $50,000
per QALY threshold, although this ﬁgure does
not serve as any boundary Laupacis et al. pro-
posed. Second, Laupacis et al. state that their
recommended boundaries were adapted from
the earlier work of Kaplan and Bush [6] in their
presentation of the “well-year”—a measure of
health-related quality of life—and its usefulness
to policy makers for making comparisons
between various health or medical programs.
Kaplan and Bush present the estimated cost per
well-year for several health programs and argue
for the use of the well-year for making compar-
isons among health programs on the basis of
their relative efﬁciency. Programs costing less
than $20,000 per well-year are considered
“cost effective by current standards;” a pro-
gram costing $20,000 to $100,000 per well-
year are “possibly controversial, but justiﬁable
by many current examples;” and programs
costing greater than $100,000 per well-year are
“questionable in comparison with other health
care expenditures [6].” All of the health pro-
grams referred to by Kaplan and Bush in their
article, such as PKU screening, tuberculin test-
ing, and estrogen therapy for postmenopausal
symptoms, among others, are based on previ-
ously published studies, save one—hospital
renal dialysis, for which estimated cost-utility is
presented as much greater than $50,000 per
well-year.
2. Hirth et al. [2] used the results of their review
of studies estimating the value of life to calcu-
late the implied value of a QALY. Depending on
the method used in the original study to calcu-
late the value of life, the reported values of a
QALY ranged from $31,000, human capital
approach, to $543,000, revealed preference/job
risk approach, with a median value of
$336,000, all in 2003 US dollars [7]. It is inter-
esting to note that the inﬂation-adjusted value
of $336,000 approximates the upper value of
the cost per well-year, $366,000 after adjust-
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ment for inﬂation, for an intervention to be
considered controversial but justiﬁable as pro-
posed by Kaplan and Bush.
To summarize, although some allocation decisions
made in the UK and Australia seem to point to
$50,000 per QALY as a cost-effectiveness thresh-
old, neither the dialysis standard nor Laupacis
et al.’s recommended guidelines for technology
adoption are the basis for this ﬁgure.
The opportunity to offer these remarks is appre-
ciated.—Franklin Laufer, PhD, AIDS Institute, New
York State Department of Health.
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